An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
OHSU Knight Cancer Institute, Portland, Oregon, United States
MD Anderson Cancer Center, Houston, Texas, United States
Universtiy of Colorado Hospital, Aurora, Colorado, United States
M D Anderson Cancer Center, Houston, Texas, United States
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
University of Florida, Gainesville, Florida, United States
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Chengdu Third People's Hospital, Chendu, Sichuan, China
People's Hospital of Deyang City, Deyang, Deyang, China
West China Hospital, Sichuan University, Chendu, Sichuan, China
M D Anderson Cancer Center, Houston, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.